Psilocybin and other psychedelic drugs may still be federally prohibited, Schedule-1 Controlled substances, ostensibly with no accepted medical use. But gold-standard research demonstrating the impressive efficacy and safety of these substances for treating intractable mental health disorders has changed minds even in the FDA. And while far from being a done deal, many expect that the rescheduling of certain psychedelic compounds, and their introduction into routine standard of care, is now just a matter of time.

In the meantime, Cybin Corp, a Canadian mushroom life sciences company, is already refining the way psilocybin can be administered. Cybin recently entered into collaboration with drug delivery company IntelGenx to create an orally dissolvable film that delivers pharmaceutical grade psilocybin to the patient.

– Read the entire article at Forbes.